Multiple ascending dose study of BMS-582949 in patients with stable rheumatoid arthritis on the methotrexate background
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2010
At a glance
- Drugs BMS 582949 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 18 Dec 2007 Status changed from in progress to completed.
- 09 Oct 2007 Status changed from recruiting to in progress.